Lantern Pharma Demonstrates withZeta.ai Platform for Rare Cancer Drug Discovery
On April 9, 2026, Lantern Pharma Inc. conducted a live demonstration and presentation of its proprietary 'withZeta.ai' platform. The platform is described as a multi-agentic AI co-scientist specifically designed for rare cancer drug discovery, development, and clinical trial design. During the demonstration, the company detailed the platform's commercial architecture, competitive positioning, and its near-term revenue strategy, which includes software licensing and subscription models. Lantern Pharma intends to leverage this AI and machine learning technology to accelerate the pace and reduce the costs and risks associated with oncology drug development. The presentation also covered the rare cancer market opportunity and the companyβs growth roadmap for the platform. This disclosure was made under Item 7.01 (Regulation FD) and does not reflect new clinical data or financial results, but rather highlights the technological capabilities and commercialization strategy for the company's AI-driven discovery tools.